We hoped this study could tell us how to get much longer remission time and lower toxicity for these patients. Researchers randomly assigned patients with EGFR mutations to receive gefitinib daily for 24 months or vinorelbine plus cisplatin chemotherapy every 3 weeks for four cycles. Follow-up for disease recurrence occurred at 3 years. Patients who received gefitinib demonstrated significantly longer median DFS than those who received chemotherapy Seventy-six patients
Gefitinib delays recurrence in some patients with lung cancer
ZD (Iressa™): For More Than Just Non-Small Cell Lung Cancer
This page contains brief information about gefitinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. FDA label information for this drug is available at DailyMed. Gefitinib is also being studied in the treatment of other types of cancer. MedlinePlus Information on Gefitinib - A lay language summary of important information about this drug that may include the following:. Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
ZD1839 (Iressa™): For More Than Just Non-Small Cell Lung Cancer
Zotero Mendeley EndNote. Targeted therapeutics due to 'selective targets' aims cancer cells with specific molecular defect thereby, kils the cancer cells, which makes it possible to continue normal cells in a healthy environment. The rapid emergence of hundreds of new agents that modulates ever-growing list of the cancer-specific molecular targets promise great hope for cancer patients. Evaluation of the target agent individually, in combination with standard therapy and other target agents bring about important development challenges.
AstraZeneca is at the forefront of research into targeted therapies for EGFR mutated lung cancer and is committed to improving the outlook for patients at all stages of the disease. The safety profile of IRESSA is well established through a large, global clinical programme and extensive real world evidence. The most commonly reported adverse events for IRESSA are diarrhoea and skin reactions including rash, acne, dry skin and pruritus. A total of EGFR mutation-positive patients were enrolled to the study.